Agios Pharmaceuticals Inc. (AGIO) Insider Scott Biller Sells 5,000 Shares
Agios Pharmaceuticals Inc. (NASDAQ:AGIO) insider Scott Biller sold 5,000 shares of the stock in a transaction that occurred on Wednesday, October 5th. The shares were sold at an average price of $55.00, for a total value of $275,000.00. Following the transaction, the insider now owns 48,270 shares in the company, valued at approximately $2,654,850. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Scott Biller also recently made the following trade(s):
- On Tuesday, September 20th, Scott Biller sold 5,000 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $50.00, for a total transaction of $250,000.00.
Agios Pharmaceuticals Inc. (NASDAQ:AGIO) opened at 52.69 on Monday. The company’s market capitalization is $2.00 billion. The firm’s 50 day moving average price is $46.07 and its 200-day moving average price is $46.30. Agios Pharmaceuticals Inc. has a one year low of $33.50 and a one year high of $81.77.
Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($1.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by $0.99. Agios Pharmaceuticals had a negative net margin of 320.33% and a negative return on equity of 47.69%. The firm earned $6.98 million during the quarter, compared to analyst estimates of $39.62 million. During the same period in the prior year, the company earned ($0.85) earnings per share. The business’s quarterly revenue was down 47.2% compared to the same quarter last year. Equities analysts forecast that Agios Pharmaceuticals Inc. will post ($5.04) earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Opaleye Management Inc. purchased a new position in shares of Agios Pharmaceuticals during the first quarter worth approximately $4,263,000. Royal Bank of Canada raised its position in shares of Agios Pharmaceuticals by 65.0% in the first quarter. Royal Bank of Canada now owns 4,465 shares of the biopharmaceutical company’s stock worth $181,000 after buying an additional 1,759 shares in the last quarter. Schonfeld Strategic Advisors LLC purchased a new position in shares of Agios Pharmaceuticals during the first quarter worth approximately $318,000. Bellevue Group AG purchased a new position in shares of Agios Pharmaceuticals during the first quarter worth approximately $2,192,000. Finally, A.R.T. Advisors LLC purchased a new position in shares of Agios Pharmaceuticals during the first quarter worth approximately $1,185,000. 81.59% of the stock is currently owned by hedge funds and other institutional investors.
AGIO has been the topic of several research analyst reports. Credit Suisse Group AG restated a “buy” rating on shares of Agios Pharmaceuticals in a research note on Tuesday, July 12th. Canaccord Genuity reaffirmed a “buy” rating and issued a $90.00 target price on shares of Agios Pharmaceuticals in a research report on Thursday, September 8th. Goldman Sachs Group Inc. reaffirmed a “hold” rating and issued a $46.00 target price on shares of Agios Pharmaceuticals in a research report on Monday, June 13th. BTIG Research started coverage on Agios Pharmaceuticals in a research report on Friday, August 19th. They issued a “neutral” rating for the company. Finally, Janney Montgomery Scott reaffirmed a “neutral” rating and issued a $47.00 target price (down from $52.00) on shares of Agios Pharmaceuticals in a research report on Monday, June 13th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $63.44.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs), which are a subset of orphan genetic metabolic diseases. Its cancer product candidates are AG-221 and AG-120, which targets mutated isocitrate dehydrogenase 2 and 1, or IDH2 and IDH1, respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Stock Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.